

Dispersed-Phase Formulation and Manufacturing

Keep your dispersed
product development
flowing smoothly.



Ready to unlock the full potential of your dispersed-phase formulations? At Baxter BioPharma Solutions, we bring together all the expertise and resources you need to formulate, scale up, and commercialize a wide variety of complex and challenging dispersed products—including

- Lipid emulsions
- Liposomes
- Lipid complexes
- Other Dispersed Products

Our senior scientists can help accelerate your product's success at all phases of development:



- Process development from lab scale to multiple-liter scale cGMP manufacturing
- Efficient formulation design
- Analytical method development and technology transfer for lipids, small molecules, and biologics

EXPANDED RESOURCES FOR RELIABLE RESULTS.

Whether you're formulating a novel biologic product or scaling up a lipid formulation, our expanded manufacturing capabilities provide exceptional flexibility and efficiency to help ensure your product is developed successfully and on schedule.

- Advanced homogenization technology
- Formulation development, process scale-up, and process control
- State-of-the-art lyophilization cycle development
- Aseptic processing expertise
- Large-scale cGMP solvent removal
- High-volume cGMP manufacturing

BioPharma Solutions

Baxter

Connect to the resources you need.



What separates Baxter BioPharma Solutions from other dispersed product manufacturers?

Manufacturing dispersed-phase formulations is highly specialized—requiring a unique combination of scientific expertise, advanced manufacturing capabilities, and dedicated project management. At Baxter, these capabilities come together to create a seamless process that helps ensure a successful transition to market for many types of dispersed products.

Case Study #1

ACCELERATING DEVELOPMENT OF cGMP CLINICAL BATCHES.

The challenge: Baxter was asked to help scale up an aseptic emulsion from 10 L to 250 L. Moreover, the customer needed efficient production of late-stage clinical batches.

The result: Through careful analysis and development, the homogenization process was scaled up from 10 L to 150 L in approximately 4 months. At the same time, homogenization time was decreased 6 fold by simulating and refining the manufacturing process. To date, multiple cGMP clinical batches have been successfully produced at the 250 L scale.

Case Study #2

STREAMLINED MANUFACTURING FOR AN ASEPTIC LIPOSOME.

The challenge: The client needed help with an aseptic liposome manufacturing process. The process needed to be scaled up to 100 L, followed by production of late-stage clinical batches.

The result: In approximately 4 months, the process was advanced from 2 L to 50 L. An innovative approach to a key manufacturing step also significantly improved efficiency—decreasing the number of processing cycles by 40%. Multiple cGMP clinical batches have been produced successfully at the 100 L scale.

Ask us today how we can help your dispersed products succeed through:

- Scientific expertise for optimized formulation
- State-of-the-art manufacturing for reliable supply
- Bottom-line cost efficiencies for enhanced market success

Call 1-800-4-BAXTER or visit www.baxterbiopharmasolutions.com.

BioPharma Solutions

Baxter

Connect to the resources you need.